Opioid analgesic exposure during the first trimester of pregnancy and the risk of major congenital malformations in infants: a systematic review and meta-analysis†
- PMID: 38715235
- DOI: 10.1111/anae.16307
Opioid analgesic exposure during the first trimester of pregnancy and the risk of major congenital malformations in infants: a systematic review and meta-analysis†
Abstract
Background: Prescribed opioid analgesics are frequently used to manage pain in pregnancy. However, the available literature regarding the teratogenic potential of opioid use during pregnancy has not been systematically summarised. This systematic review and meta-analysis aimed to assess the quality of the evidence on these potential risks and calculate a pooled estimate of risk for any opioid analgesic and individual opioids.
Methods: We searched PubMed, Embase and CINAHL for published studies assessing the risk of major congenital malformations in infants following first-trimester exposure to opioid analgesics compared with a reference group, excluding studies examining opioid agonist therapy or illicit opioid use. We assessed the risk of bias using the Risk of Bias in Non-Randomised Studies of Intervention tool. We pooled adjusted risk estimates from studies rated at serious risk of bias or better in a random-effects meta-analysis.
Results: Of 12 identified studies, 11 were at high risk of bias (eight serious; three critical). Relative to unexposed infants, those exposed to any opioid use during the first trimester of pregnancy were not at an increased risk of major congenital malformations overall (relative risk 1.04, 95%CI 0.98-1.11); cardiovascular malformations (relative risk 1.07, 95%CI 0.96-1.20); or central nervous system malformations (relative risk 1.06, 95%CI 0.92-1.21). Raised risk estimates were observed for gastrointestinal malformations (relative risk 1.40, 95%CI 0.38-5.16) and cleft palate (relative risk 1.57, 95%CI 0.48-5.13) following any opioid exposure and atrial septal defects (relative risk 1.20, 95%CI 1.05-1.36) following codeine exposure.
Conclusions: Although the meta-analysis did not indicate substantial increased risk for most malformations examined, this risk remains uncertain due to the methodological limitations of the included studies. Healthcare professionals and pharmaceutical regulators should be aware of the issues related to the quality of research in this field.
Keywords: abnormalities; birth defects; congenital malformations; opioid analgesics; pregnancy.
© 2024 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists.
References
-
- Twigg MJ, Lupattelli A, Nordeng H. Women's beliefs about medication use during their pregnancy: a UK perspective. Int J Clin Pharm 2016; 38: 968–976. https://doi.org/10.1007/s11096‐016‐0322‐5.
-
- Australian Government, Therapeutic Goods Administration. Nonsteroidal anti‐inflammatory drugs (NSAIDs) and spontaneous abortion. Pharmacovigilance and Special Access Branch Safety Review 2016. https://www.tga.gov.au/sites/default/files/safety‐review‐nonsteroidal‐an... (accessed 09/04/2024).
-
- Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975; 4: 37–44. https://doi.org/10.1093/ije/4.1.37.
-
- Wang X, Wang Y, Tang B, Feng X. Opioid exposure during pregnancy and the risk of congenital malformation: a meta‐analysis of cohort studies. BMC Pregnancy Childbirth 2022; 22: 401. https://doi.org/10.1186/s12884‐022‐04733‐9.
-
- Huybrechts KF, Bateman BT, Hernandez‐Diaz S. Use of real‐world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiol Drug Saf 2019; 28: 906–922. https://doi.org/10.1002/pds.4789.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical